HealthEquity Reports Second Quarter Ended July 31, 2022 Financial Results

Rhea-AI Summary

HealthEquity (HQY) reported a Q2 FY23 revenue of $206.1 million, a 9% increase from $189.1 million in Q2 FY22. However, the company incurred a net loss of $10.7 million, compared to a loss of $3.8 million in the same quarter last year. Non-GAAP net income decreased by 16% to $28.1 million, with earnings per diluted share of $0.33, down from $0.40. Adjusted EBITDA rose 2% to $67.0 million. The company saw 7.5 million HSAs, a 26% increase year-over-year, and total HSA assets grew 33% to $20.5 billion.

Positive

• Revenue increased 9% to $206.1 million.
• Total HSA Assets rose by 33% to $20.5 billion.
• Adjusted EBITDA up 2% at $67 million.

Negative

• Net loss increased to $10.7 million from $3.8 million.
• Non-GAAP net income decreased 16% to $28.1 million.
• Earnings per diluted share fell to $0.33 from $0.40.

Highlights of the second quarter include:

• Revenue of $206.1 million, an increase of 9% compared to $189.1 million in Q2 FY22.
• Net loss of $10.7 million, compared to $3.8 million in Q2 FY22, with non-GAAP net income of $28.1 million, a decrease of 16% compared to $33.4 million in Q2 FY22.
• Net loss per diluted share of $0.13, compared to $0.05 in Q2 FY22, with non-GAAP net income per diluted share of $0.33, compared to $0.40 in Q2 FY22.
• Adjusted EBITDA of $67.0 million, an increase of 2% compared to $65.5 million in Q2 FY22.
• 7.5 million HSAs, an increase of 26% compared to Q2 FY22.
• Total HSA Assets of $20.5 billion, an increase of 33% compared to Q2 FY22.
• 14.5 million Total Accounts, including both HSAs and complementary CDB accounts, an increase of 11% compared to Q2 FY22.

DRAPER, Utah, Sept. 06, 2022 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") non-bank custodian, today announced financial results for its second quarter ended July 31, 2022.

"Team Purple opened a record 196,000 new HSAs in Q2 and grew Total HSA Assets 33% year-over-year to an industry-leading $20.5 billion," said Jon Kessler, President and CEO of HealthEquity. "Sales momentum, macro tailwinds, and a team focused on remarkable service position us for strong results in fiscal 2023 and beyond."

Second quarter financial results

Revenue for the second quarter ended July 31, 2022 was $206.1 million, an increase of 9% compared to $189.1 million for the second quarter ended July 31, 2021. Revenue this quarter included: service revenue of $103.0 million, custodial revenue of $65.6 million, and interchange revenue of $37.5 million.

HealthEquity reported a net loss of $10.7 million, or $0.13 per diluted share, and non-GAAP net income of $28.1 million, or $0.33 per diluted share, for the second quarter ended July 31, 2022. The Company reported a net loss of $3.8 million, or $0.05 per diluted share, and non-GAAP net income of $33.4 million, or $0.40 per diluted share, for the second quarter ended July 31, 2021.

Adjusted EBITDA was $67.0 million for the second quarter ended July 31, 2022, an increase of 2% compared to the second quarter ended July 31, 2021. Adjusted EBITDA was 33% of revenue, compared to 35% for the fiscal quarter ended July 31, 2021.

Account and asset metrics

HealthEquity reported sales of 196,000 new HSAs in the second quarter ended July 31, 2022, compared to 180,000 in the second quarter ended July 31, 2021. HSAs as of July 31, 2022 were 7.5 million, an increase of 26% year over year, including 516,000 HSAs with investments, an increase of 28% year over year. Total Accounts as of July 31, 2022 were 14.5 million, including 7.0 million other consumer-directed benefits ("CDBs").

Total HSA Assets as of July 31, 2022 were $20.5 billion, an increase of 33% year over year. Total HSA Assets included $13.1 billion of HSA cash and $7.4 billion of HSA investments. Client-held funds, which are deposits held on behalf of our Clients to facilitate administration of our CDBs, and from which we generate custodial revenue, were $0.8 billion as of July 31, 2022.

Business outlook

For the fiscal year ending January 31, 2023, management expects revenues of $834 million to $844 million. Its outlook for net loss is between $43 million and $36 million, resulting in net loss of $0.51 to $0.43 per diluted share. Its outlook for non-GAAP net income, calculated using the method described below, is between $103 million and $111 million, resulting in non-GAAP net income per diluted share of $1.23 to $1.32 (based on an estimated 84 million diluted weighted-average shares outstanding). Management expects Adjusted EBITDA of $252 million to $262 million.

See “Non-GAAP financial information” below for definitions of our Adjusted EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.

Conference call

HealthEquity management will host a conference call at 4:30 pm (Eastern Time) on Tuesday, September 6, 2022 to discuss the second quarter 2023 financial results. A live audio webcast of the call will be available on the investor relations section of our website at http://ir.healthequity.com.

Non-GAAP financial information

To supplement our financial information presented on a GAAP basis, we disclose non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share.

• Adjusted EBITDA is adjusted earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.
• Non-GAAP net income is calculated by adding back to GAAP net income (loss) before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
• Non-GAAP net income per diluted share is calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.

Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. In addition, while amortization of acquired intangible assets is being excluded from non-GAAP net income, the revenue generated from those acquired intangible assets is not excluded. Whenever we use these non-GAAP financial measures, we provide a reconciliation of the applicable non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed in the tables below.

About HealthEquity

HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for our more than 14 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to connect health and wealth and value our culture of remarkable “Purple” service. For more information, visit www.healthequity.com.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.

Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:

• the impact of societal and economic changes arising out of the COVID-19 pandemic on the Company, its operations and its financial results;
• our ability to realize the anticipated financial and other benefits from combining the operations of recent and future acquisitions with our business successfully;
• our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;
• our dependence on the continued availability and benefits of tax-advantaged health savings accounts and other consumer-directed benefits;
• our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;
• the significant competition we face and may face in the future, including from those with greater resources than us;
• our reliance on the availability and performance of our technology and communications systems;
• potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;
• the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;
• our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;
• our reliance on partners and third-party vendors for distribution and important services;
• our ability to develop and implement updated features for our technology and communications systems and successfully manage our growth;
• our ability to protect our brand and other intellectual property rights; and
• our reliance on our management team and key team members.

For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2022, our Quarterly Report on Form 10-Q for the quarter ended April 30, 2022, and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact
Richard Putnam
801-727-1209
rputnam@healthequity.com

HealthEquity, Inc. and its subsidiaries
Condensed consolidated balance sheets

(in thousands, except par value)	July 31, 2022			January 31, 2022
	(unaudited)
Assets
Current assets
Cash and cash equivalents	$	176,886		$	225,414
Accounts receivable, net of allowance for doubtful accounts of $6,215 and $6,228 as of July 31, 2022 and January 31, 2022, respectively		90,426			87,428
Other current assets		41,274			38,495
Total current assets		308,586			351,337
Property and equipment, net		18,028			23,372
Operating lease right-of-use assets		60,588			63,613
Intangible assets, net		991,945			973,137
Goodwill		1,645,999			1,645,836
Other assets		48,878			49,807
Total assets	$	3,074,024		$	3,107,102
Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	15,841		$	27,541
Accrued compensation		41,989			47,136
Accrued liabilities		43,287			57,589
Current portion of long-term debt		13,125			8,750
Operating lease liabilities		11,275			12,171
Total current liabilities		125,517			153,187
Long-term liabilities
Long-term debt, net		914,966			922,077
Operating lease liabilities, non-current		62,626			65,232
Other long-term liabilities		13,731			14,185
Deferred tax liability		92,288			99,846
Total long-term liabilities		1,083,611			1,101,340
Total liabilities		1,209,128			1,254,527
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2022 and January 31, 2022, respectively		—			—
Common stock, $0.0001 par value, 900,000 shares authorized, 84,526 and 83,780 shares issued and outstanding as of July 31, 2022 and January 31, 2022, respectively		8			8
Additional paid-in capital		1,713,122			1,676,508
Accumulated earnings		151,766			176,059
Total stockholders’ equity		1,864,896			1,852,575
Total liabilities and stockholders’ equity	$	3,074,024		$	3,107,102

HealthEquity, Inc. and its subsidiaries
Condensed consolidated statements of operations and comprehensive loss (unaudited)

	Three months ended July 31,								Six months ended July 31,
(in thousands, except per share data)		2022				2021				2022				2021
Revenue
Service revenue	$	103,034			$	109,182			$	207,382			$	211,716
Custodial revenue		65,599				48,776				124,964				95,754
Interchange revenue		37,509				31,145				79,475				65,835
Total revenue		206,142				189,103				411,821				373,305
Cost of revenue
Service costs		74,914				67,334				155,788				137,966
Custodial costs		7,090				4,824				13,731				9,833
Interchange costs		6,326				4,974				13,317				10,419
Total cost of revenue		88,330				77,132				182,836				158,218
Gross profit		117,812				111,971				228,985				215,087
Operating expenses
Sales and marketing		15,843				15,476				32,403				29,562
Technology and development		46,580				37,898				91,763				73,367
General and administrative		25,937				22,812				49,664				43,499
Amortization of acquired intangible assets		24,181				20,289				47,879				40,103
Merger integration		7,683				16,371				16,977				25,178
Total operating expenses		120,224				112,846				238,686				211,709
Income (loss) from operations		(2,412	)			(875	)			(9,701	)			3,378
Other expense
Interest expense		(11,493	)			(7,254	)			(21,954	)			(13,943	)
Other income (expense), net		32				344				(269	)			(3,286	)
Total other expense		(11,461	)			(6,910	)			(22,223	)			(17,229	)
Loss before income taxes		(13,873	)			(7,785	)			(31,924	)			(13,851	)
Income tax benefit		(3,219	)			(3,967	)			(7,631	)			(7,418	)
Net loss and comprehensive loss	$	(10,654	)		$	(3,818	)		$	(24,293	)		$	(6,433	)
Net loss per share:
Basic	$	(0.13	)		$	(0.05	)		$	(0.29	)		$	(0.08	)
Diluted	$	(0.13	)		$	(0.05	)		$	(0.29	)		$	(0.08	)
Weighted-average number of shares used in computing net loss per share:
Basic		84,443				83,481				84,236				82,628
Diluted		84,443				83,481				84,236				82,628

HealthEquity, Inc. and its subsidiaries
Condensed consolidated statements of cash flows (unaudited)

	Six months ended July 31,
(in thousands)		2022				2021
Cash flows from operating activities:
Net loss	$	(24,293	)		$	(6,433	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization		80,226				64,819
Stock-based compensation		32,140				28,416
Amortization of debt discount and issuance costs		1,639				2,482
Change in fair value of contingent consideration		—				1,011
Other non-cash items		269				(752	)
Deferred taxes		(7,558	)			(4,051	)
Changes in operating assets and liabilities:
Accounts receivable, net		(3,161	)			(230	)
Other assets		(1,546	)			20,636
Operating lease right-of-use assets		4,117				6,060
Accrued compensation		(4,973	)			(10,639	)
Accounts payable, accrued liabilities, and other current liabilities		(25,586	)			(30,213	)
Operating lease liabilities, non-current		(3,594	)			(4,556	)
Other long-term liabilities		(454	)			1,616
Net cash provided by operating activities		47,226				68,166
Cash flows from investing activities:
Purchases of software and capitalized software development costs		(24,215	)			(32,097	)
Purchases of property and equipment		(2,384	)			(6,352	)
Acquisition of intangible member assets		(68,725	)			(2,653	)
Acquisitions, net of cash acquired		—				(49,533	)
Proceeds from sale of equity securities		—				2,367
Net cash used in investing activities		(95,324	)			(88,268	)
Cash flows from financing activities:
Principal payments on long-term debt		(4,375	)			(15,625	)
Settlement of client-held funds obligation, net		(991	)			(2,636	)
Proceeds from exercise of common stock options		4,936				6,672
Proceeds from follow-on equity offering, net of payments for offering costs		—				456,642
Net cash provided by (used in) financing activities		(430	)			445,053
Increase (decrease) in cash and cash equivalents		(48,528	)			424,951
Beginning cash and cash equivalents		225,414				328,803
Ending cash and cash equivalents	$	176,886			$	753,754

HealthEquity, Inc. and its subsidiaries
Condensed consolidated statements of cash flows (unaudited) (continued)

	Six months ended July 31,
(in thousands)		2022			2021
Supplemental cash flow data:
Interest expense paid in cash	$	19,450		$	9,838
Income tax payments (refunds), net		573			(5,545	)
Supplemental disclosures of non-cash investing and financing activities:
Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation		5,040			4,077
Purchases of property and equipment included in accounts payable or accrued liabilities		356			357
Purchases of intangible member assets included in accounts payable or accrued liabilities		1,849			—
Contingent consideration recognized at acquisition		—			8,147
Exercise of common stock options receivable		8			119
Increase in goodwill due to measurement period adjustments, net		163			—

Stock-based compensation expense (unaudited)

Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss is as follows:

	Three months ended July 31,						Six months ended July 31,
(in thousands)		2022			2021			2022			2021
Cost of revenue	$	3,998		$	3,068		$	7,005		$	5,471
Sales and marketing		2,553			2,660			4,567			4,848
Technology and development		2,963			3,693			6,343			6,706
General and administrative		8,640			6,196			14,225			11,391
Other expense, net (1)		—			—			—			342
Total stock-based compensation expense	$	18,154		$	15,617		$	32,140		$	28,758

(1)   Equity-based awards exchanged for cash in connection with the Luum acquisition.

Total Accounts (unaudited)

(in thousands, except percentages)	July 31, 2022		July 31, 2021		% Change		January 31, 2022
HSAs	7,523		5,972		26%		7,207
New HSAs from sales - Quarter-to-date	196		180		9%		472
New HSAs from sales - Year-to-date	355		295		20%		918
New HSAs from acquisitions - Year-to-date	90		—		n/a		740
HSAs with investments	516		402		28%		455
CDBs	7,023		7,171		(2)%		7,192
Total Accounts	14,546		13,143		11%		14,399
Average Total Accounts - Quarter-to-date	14,497		13,358		9%		14,326
Average Total Accounts - Year-to-date	14,462		13,114		10%		13,450

HSA Assets (unaudited)

(in millions, except percentages)	July 31, 2022			July 31, 2021			% Change		January 31, 2022
HSA cash	$	13,097		$	10,028		31%		$	12,943
HSA investments		7,441			5,443		37%			6,675
Total HSA Assets		20,538			15,471		33%			19,618
Average daily HSA cash - Year-to-date		12,924			10,007		29%			10,579
Average daily HSA cash - Quarter-to-date		12,941			9,963		30%			12,118

Client-held funds (unaudited)

(in millions, except percentages)	July 31, 2022			July 31, 2021			% Change		January 31, 2022
Client-held funds	$	801		$	810		(1)%		$	897
Average daily Client-held funds - Year-to-date		852			876		(3)%			842
Average daily Client-held funds - Quarter-to-date		839			853		(2)%			822

Reconciliation of net loss to Adjusted EBITDA (unaudited)

	Three months ended July 31,								Six months ended July 31,
(in thousands)		2022				2021				2022				2021
Net loss	$	(10,654	)		$	(3,818	)		$	(24,293	)		$	(6,433	)
Interest income		(89	)			(533	)			(141	)			(941	)
Interest expense		11,493				7,254				21,954				13,943
Income tax benefit		(3,219	)			(3,967	)			(7,631	)			(7,418	)
Depreciation and amortization		16,559				12,762				32,347				24,716
Amortization of acquired intangible assets		24,181				20,289				47,879				40,103
Stock-based compensation expense		18,154				15,617				32,140				28,416
Merger integration expenses		7,683				16,371				16,977				25,178
Acquisition costs (1)		47				1,665				53				7,604
Gain on equity securities		—				(1,677	)			—				(1,677	)
Amortization of incremental costs to obtain a contract		1,074				1,352				2,142				2,624
Costs associated with unused office space		1,313				—				2,607				—
Other		501				200				1,345				(1,625	)
Adjusted EBITDA	$	67,043			$	65,515			$	125,379			$	124,490

(1)   For the six months ended July 31, 2021, acquisition costs included $0.3 million of stock-based compensation expense.

Reconciliation of net loss outlook to Adjusted EBITDA outlook (unaudited)

	Outlook for the year ending
(in millions)	January 31, 2023
Net loss	$(43) - (36)
Interest expense	46
Income tax benefit	(15) - (12)
Depreciation and amortization	64
Amortization of acquired intangible assets	97
Stock-based compensation expense	67
Merger integration expenses	27
Amortization of incremental costs to obtain a contract	4
Costs associated with unused office space	5
Adjusted EBITDA	$252 - 262

Reconciliation of net loss to non-GAAP net income (unaudited)

	Three months ended July 31,								Six months ended July 31,
(in thousands, except per share data)		2022				2021				2022				2021
Net loss	$	(10,654	)		$	(3,818	)		$	(24,293	)		$	(6,433	)
Income tax benefit		(3,219	)			(3,967	)			(7,631	)			(7,418	)
Loss before income taxes - GAAP		(13,873	)			(7,785	)			(31,924	)			(13,851	)
Non-GAAP adjustments:
Amortization of acquired intangible assets		24,181				20,289				47,879				40,103
Stock-based compensation expense		18,154				15,617				32,140				28,416
Merger integration expenses		7,683				16,371				16,977				25,178
Acquisition costs		47				1,665				53				7,604
Gain on equity securities		—				(1,677	)			—				(1,677	)
Costs associated with unused office space		1,313				—				2,607				—
Total adjustments to loss before income taxes - GAAP		51,378				52,265				99,656				99,624
Income before income taxes - Non-GAAP		37,505				44,480				67,732				85,773
Income tax provision - Non-GAAP (1)		9,376				11,120				16,933				21,443
Non-GAAP net income		28,129				33,360				50,799				64,330
Diluted weighted-average shares		84,443				83,481				84,236				82,628
Non-GAAP net income per diluted share	$	0.33			$	0.40			$	0.60			$	0.78

(1)   The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

Reconciliation of net loss outlook to non-GAAP net income outlook (unaudited)

	Outlook for the year ending
(in millions, except per share data)	January 31, 2023
Net loss	$(43) - (36)
Income tax benefit	(15) - (12)
Loss before income taxes - GAAP	(58) - (48)
Non-GAAP adjustments:
Amortization of acquired intangible assets	97
Stock-based compensation expense	67
Merger integration expenses	27
Costs associated with unused office space	5
Total adjustments to loss before income taxes - GAAP	196
Income before income taxes - Non-GAAP	138 - 148
Income tax provision - Non-GAAP (1)	35 - 37
Non-GAAP net income	$103 - 111
Diluted weighted-average shares	84
Non-GAAP net income per diluted share (2)	$1.23 - 1.32

(1)   The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

(2)   Non-GAAP net income per diluted share may not calculate due to rounding of non-GAAP net income and diluted weighted-average shares.

Certain terms

Term	Definition
HSA	A financial account through which consumers spend and save long-term for healthcare on a tax-advantaged basis.
CDB	Consumer-directed benefits offered by employers, including flexible spending and health reimbursement arrangements (“FSAs” and “HRAs”), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, commuter and other benefits.
HSA member	Consumers with HSAs that we serve.
Total HSA Assets	HSA members’ custodial cash assets held by our federally insured depository partners and our insurance company partners. Total HSA Assets also includes HSA members' investments in mutual funds through our custodial investment fund partner.
Client	Our employer clients.
Total Accounts	The sum of HSAs and CDBs on our platforms.
Client-held funds	Deposits held on behalf of our Clients to facilitate administration of our CDBs.
Network Partner	Our health plan partners, benefits administrators, and retirement plan recordkeepers.
Adjusted EBITDA	Adjusted earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.
Non-GAAP net income	Calculated by adding back to GAAP net income (loss) before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
Non-GAAP net income per diluted share	Calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.

FAQ

What were HealthEquity's financial results for Q2 FY23?

HealthEquity reported Q2 FY23 revenue of $206.1 million and a net loss of $10.7 million.

How much did HealthEquity's total HSA assets grow in Q2 FY23?

Total HSA assets increased by 33% to $20.5 billion in Q2 FY23.

What is the outlook for HealthEquity's revenues for FY23?

Management expects revenues between $834 million and $844 million for FY23.

What was the adjusted EBITDA for HealthEquity in Q2 FY23?

Adjusted EBITDA for Q2 FY23 was $67.0 million, a 2% increase from the previous year.